NCT03586297View on ClinicalTrials.gov

Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer

CompletedOBSERVATIONAL
Enrollment

49

Participants

Timeline

Start Date

August 27, 2017

Primary Completion Date

September 15, 2025

Study Completion Date

September 15, 2025

Conditions
Triple Negative Breast Cancer
Trial Locations (3)

20057

Georgetown University, Washington D.C.

06520-8327

Yale University - Yale Cancer Center, New Haven

07601

Hackensack Meridian Health, Hackensack

Sponsors
All Listed Sponsors
collaborator

Breast Cancer Research Foundation

OTHER

lead

Hackensack Meridian Health

OTHER